Bio-Rad Laboratories, Inc. (BIO) Receives $314.00 Average PT from Analysts
Bio-Rad Laboratories, Inc. (NYSE:BIO) has been assigned an average rating of “Buy” from the nine analysts that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $314.00.
A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, August 13th. Barclays began coverage on Bio-Rad Laboratories in a report on Wednesday, September 5th. They issued an “equal weight” rating and a $345.00 price objective on the stock. Finally, Jefferies Financial Group upped their target price on Bio-Rad Laboratories from $325.00 to $355.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th.
Institutional investors have recently made changes to their positions in the business. Ostrum Asset Management bought a new stake in Bio-Rad Laboratories during the first quarter worth approximately $121,000. Eagle Boston Investment Management Inc. bought a new stake in shares of Bio-Rad Laboratories in the first quarter valued at approximately $206,000. Raymond James Trust N.A. bought a new stake in shares of Bio-Rad Laboratories in the second quarter valued at approximately $212,000. World Asset Management Inc bought a new stake in shares of Bio-Rad Laboratories in the second quarter valued at approximately $213,000. Finally, Cigna Investments Inc. New bought a new stake in shares of Bio-Rad Laboratories in the first quarter valued at approximately $219,000. 63.19% of the stock is owned by hedge funds and other institutional investors.
Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Tuesday, August 7th. The medical research company reported $1.64 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.37. Bio-Rad Laboratories had a return on equity of 4.23% and a net margin of 44.77%. The firm had revenue of $575.91 million for the quarter, compared to the consensus estimate of $551.05 million. sell-side analysts forecast that Bio-Rad Laboratories will post 6.1 earnings per share for the current fiscal year.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Featured Story: Diversification in Investing
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.